Journal
HUMAN VACCINES
Volume 5, Issue 3, Pages 141-150Publisher
LANDES BIOSCIENCE
DOI: 10.4161/hv.5.3.6589
Keywords
HIV; vaccine; adjuvant
Categories
Funding
- NIH [1R43 AI065289]
- CNPRC Operating [P51 RR00169]
Ask authors/readers for more resources
This pilot study tested the immunogenicity of a novel cationic liposome-DNA complex (CLDC) immunomodulatory vaccine adjuvant. Combined with a specific antigen, CLDC enhanced anti-SIV immune responses induced by various SIV vaccine candidates. Rhesus macaques immunized in the presence of CLDC developed stronger SIV-specific T and B cell responses compared to animals immunized without CLDC. These differences persisted and resulted in better memory responses after an in vivo boost of the animals several months later with whole AT-2 inactivated SIVmac239. Thus, CLDC should be explored further as a potential immunomodulatory adjuvant in HIV vaccine design.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available